Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...

The trade threats could reduce exports to the United States and dampen investment in Europe, dealing a blow to growth at a ...

One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics ( GPCR 0.16%), was a victim of a ...

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

Kingsview Wealth Management LLC reduced its holdings in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 76.9% during the 4th quarter, according to the company in its most recent 13F filing with ...

Bank of America Securities analyst Sachin Jain maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Long-Term Pick. In this article, we will summarize ...

The “Check Before You Inject” ad goes on to note that some vials of compounded semaglutide “have been found to contain ...

The Hims & Hers version of the weight-loss drug is a compounded drug, essentially a mixture of individual drugs that creates ...